PRANJAL SARMA

Dr. PRANJAL SARMA

College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Bioresource Technology
Verified
Journal Article
Closed access
MBM. Lenin Babu
M. Lenin Babu
GSG. Venkata Subhash
G. Venkata Subhash
PSPRANJAL SARMA
PRANJAL SARMA
SMS. Venkata Mohan
S. Venkata Mohan

1 November 2013 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AKAhmed Kamal
Ahmed Kamal
JTJaki R. Tamboli
Jaki R. Tamboli
MRM. Janaki Ramaiah
M. Janaki Ramaiah
Syed Farooq AdilSyed Farooq Adil
Syed Farooq Adil
SPS.N.C.V.L. Pushpavalli
S.N.C.V.L. Pushpavalli
MPManika Pal-Bhadra
Manika Pal-Bhadra

11 November 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
Chenran WangChenran Wang
Chenran Wang
MHMichael A. Haas
Michael A. Haas
FYFuchun Yang
Fuchun Yang
Syn Kok YeoSyn Kok Yeo
Syn Kok Yeo
TOTakako Okamoto
Takako Okamoto
JGJun-Lin Guan
Jun-Lin Guan

1 January 2009 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SPShinde Santosh P.
Shinde Santosh P.
NANeelima Arora
Neelima Arora
PSPRANJAL SARMA
PRANJAL SARMA
MPManika Pal-Bhadra
Manika Pal-Bhadra
UBUtpal Bhadra
Utpal Bhadra
Parkinson′s disease (PD) is a complex multigenic neurodisorder frequently occurring in elderly persons. To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3′UTR using TargetScan (version 5.1). Data extracted by miRanda elucidates the mode of microRNA action based on the location of target sites in the Parkinson genes. Sites prone to action of multiple miRNAs were identified as “hot spots.” Important properties of each miRNA including multiplicity and cooperativity appear to contribute towards a complex interplay between miRNAs and their targets. Two sets of predicted results were explored for the occurrence of target sites of 112 miRNAs expressed in midbrain. Overall, convergence of results predicted by two algorithms revealed that 48 target sites for midbrain‐specific miRNA occur in close proximity in 9 genes. This study will pave a way for selection of potential miRNA candidates for Parkinson′s disease‐related genes for quick therapeutic applications and diagnosis.

1 February 2017 in Cell Reports
Verified
Journal Article
Open access
HLHongqi Liu
Hongqi Liu
XFXizhi Feng
Xizhi Feng
KEKelli N. Ennis
Kelli N. Ennis
CBCatherine A. Behrmann
Catherine A. Behrmann
PSPRANJAL SARMA
PRANJAL SARMA
DPDavid R. Plas
David R. Plas
Genetic S6K1 inactivation can induce apoptosis in PTEN-deficient cells. We analyzed the therapeutic potential of S6K1 inhibitors in PTEN-deficient T cell leukemia and glioblastoma. Results revealed that the S6K1 inhibitor LY-2779964 was relatively ineffective as a single agent, while S6K1-targeting AD80 induced cytotoxicity selectively in PTEN-deficient cells. In vivo, AD80 rescued 50% of mice transplanted with PTEN-deficient leukemia cells. Cells surviving LY-2779964 treatment exhibited inhibitor-induced S6K1 phosphorylation due to increased mTOR-S6K1 co-association, which primed the rapid recovery of S6K1 signaling. In contrast, AD80 avoided S6K1 phosphorylation and mTOR co-association, resulting in durable suppression of S6K1-induced signaling and protein synthesis. Kinome analysis revealed that AD80 coordinately inhibits S6K1 together with the TAM family tyrosine kinase AXL. TAM suppression by BMS-777607 or genetic knockdown potentiated cytotoxic responses to LY-2779964 in PTEN-deficient glioblastoma cells. These results reveal that combination targeting of S6K1 and TAMs is a potential strategy for treatment of PTEN-deficient malignancy.

1 September 2010 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AKAhmed Kamal
Ahmed Kamal
DDD. Dastagiri
D. Dastagiri
MRM. Janaki Ramaiah
M. Janaki Ramaiah
EBE. Vijaya Bharathi
E. Vijaya Bharathi
JRJ. Surendranadha Reddy
J. Surendranadha Reddy
SZSurekha Zingde
Surekha Zingde